Back
Cross-talk between tumors can affect responses to therapy.
Journal article

Cross-talk between tumors can affect responses to therapy.

  • Devaud C Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ;
  • John LB Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ;
  • Westwood JA Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ;
  • Yong CS Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ;
  • Beavis PA Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ;
  • Schwendener RA Institute of Molecular Cancer Research; University of Zurich ; Zurich, Switzerland ;
  • Darcy PK Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ; ; Department of Immunology; Monash University ; Prahran, Victoria, Australia.
  • Kershaw MH Cancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Australia ; ; Department of Immunology; Monash University ; Prahran, Victoria, Australia.
Show more…
  • 2015-07-04
Published in:
  • Oncoimmunology. - 2015
C-C motif ligand-2; CD
CCL2
CD137
CD40
DR5
T cell receptor.
clodronate
cluster of differentiation; IFNγ
immunosuppression
immunotherapy
interferon gamma; IH
interleukin; M2
intrahepatic; IK
intrakidney; IL
natural killer; SC
subcutaneous; TCR
tumor immunology
tumor microenvironment
type 2 macrophages; NK
type-2 macrophages
English Advanced stages of cancer often involve multiple tumors in different locations in the body. These tumors are associated with a microenvironment that can influence tumor responses to immunotherapy. Whether tumors and their disparate microenvironment can interact together at distance in a multiple tumor setting, through a form of cross-talk, and affect their responses to immunotherapy has never been described. Our study investigated the cross-talk between two tumors with disparate microenvironments in a mouse model. We demonstrated that immunosuppressive visceral tumors could influence distant subcutaneous (SC) tumors to render them resistant to immunotherapy. We observed distinct modifications in the SC tumor microenvironment following cross-talk with kidney tumors that exhibit a type-2 macrophage-related immunosuppressive microenvironment. Indeed, when a concomitant kidney tumor was present in the mouse, the SC tumors were highly infiltrated with M2 macrophages and had a reduced T cell and NK cell effector immune profile. Finally, blocking the M2-associated chemokine CCL2 or depleting macrophages, significantly improved the effect of immunotherapy on growth of SC tumors in the presence of concomitant kidney tumors. This work emphasizes the potential negative influence that a tumor, with a strong immunosuppressive microenvironment, can exert on distant tumors that would normally be treatment-responsive. This report may lead to a new vision of the prioritization in the treatment of advanced metastatic cancer.
Language
  • English
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/12145
Statistics
Document views: 26 File downloads: